Propanc Biopharma, Inc. Common Stock (PPCB) - Total Liabilities
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has total liabilities worth $4.66 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Propanc Biopharma, Inc. Common Stock cash flow conversion to assess how effectively this company generates cash.
Propanc Biopharma, Inc. Common Stock - Total Liabilities Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See PPCB total equity for net asset value and shareholders' equity analysis.
Propanc Biopharma, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fluicell AB
ST:FLUI
|
Sweden | Skr5.58 Million |
|
CPT GLOBAL LTD
F:714
|
Germany | €8.09 Million |
|
Luxbright AB
ST:LXB
|
Sweden | Skr12.49 Million |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
USA | $675.92K |
|
AFC Energy plc
LSE:AFC
|
UK | GBX6.35 Million |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
USA | $39.88 Million |
|
Constellation Technologies Ltd
AU:CT1
|
Australia | AU$793.97K |
Liability Composition Analysis (2010–2025)
This chart breaks down Propanc Biopharma, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PPCB market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Propanc Biopharma, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual total liabilities of Propanc Biopharma, Inc. Common Stock from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $5.73 Million | +48.66% |
| 2024-06-30 | $3.85 Million | +21.21% |
| 2023-06-30 | $3.18 Million | +2.33% |
| 2022-06-30 | $3.11 Million | +0.80% |
| 2021-06-30 | $3.08 Million | -17.63% |
| 2020-06-30 | $3.74 Million | -15.06% |
| 2019-06-30 | $4.40 Million | -35.47% |
| 2018-06-30 | $6.82 Million | +23.24% |
| 2017-06-30 | $5.54 Million | +88.04% |
| 2016-06-30 | $2.94 Million | -20.00% |
| 2015-06-30 | $3.68 Million | +141.82% |
| 2014-06-30 | $1.52 Million | +91.64% |
| 2013-06-30 | $794.22K | +35.95% |
| 2012-06-30 | $584.19K | +90.38% |
| 2011-06-30 | $306.85K | +32.97% |
| 2010-06-30 | $230.76K | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more